Perioperative management of antiplatelet-drugs in cardiac surgery.
ABSTRACT The management of coronary patients scheduled for a coronary artery bypass grafting (CABG), who are receiving one or more antiplatelet drugs, is plenty of controversies. It has been shown that withdrawal of antiplatelet drugs is associated with an increased risk of a thrombotic event, but surgery under an altered platelet function also means an increased risk of bleeding in the perioperative period. Because of the conflict recommendations, this review article tries to evaluate the outcome of different perioperative antiplatelet protocols in patients with coronary artery disease undergoing CABG.
- ACC Current Journal Review 08/2005; 14(8):49.
- [show abstract] [hide abstract]
ABSTRACT: Oral antiplatelet agents (OAAs) can prevent further vascular events in cardiovascular disease. How prior use or recent discontinuation of OAA affects clinical presentation of acute coronary syndromes (ACS) and clinical outcomes (death, myocardial infarction [MI]) is unclear. We studied and followed up for up to 30 days a cohort of 1358 consecutive patients admitted for a suspected ACS; of these, 930 were nonusers, 355 were prior users of OAA, and 73 had recently withdrawn OAA. Nonusers were at lower risk, more frequently presented with ST-elevation MI on admission, and more frequently had Q-wave MI at discharge than prior users (36.6% versus 17.5%, P<0.001; and 47.8% versus 28.2%, P<0.001, respectively). However, there was no difference regarding the incidence of death or MI at 30 days between nonusers and prior users (10.3% versus 12.4%, P=NS). In addition, prior users experienced more major bleeds within 30 days compared with nonusers (3.4% versus 1.4%, respectively; P=0.04). Recent withdrawers were admitted on average 11.9+/-0.8 days after OAA withdrawal. Interruption was primarily a physician decision for scheduled surgery (n=47 of 73). Despite a similar cardiovascular risk profile, recent withdrawers had higher 30-day rates of death or MI (21.9% versus 12.4%, P=0.04) and bleedings (13.7% versus 5.9%, P=0.03) than prior users. After multivariate analysis, OAA withdrawal was found to be an independent predictor of both mortality and bleedings at 30 days. Among ACS patients, prior users represent a higher-risk population and present more frequently with non-ST-elevation ACS than nonusers. Although patients with a recent interruption of OAA resemble those chronically treated by OAA, they display worse clinical outcomes.Circulation 11/2004; 110(16):2361-7. · 15.20 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: We sought to determine whether aspirin withdrawal is an encountered situation in coronary disease patients who relapsed. Despite the recognized benefits of aspirin in coronary disease, and because of the threat of bleeding or poor compliance, aspirin intake is sometimes stopped. It is not known whether withdrawal of aspirin can be harmful in coronary-disease patients. Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had been interrupted. Fifty-one of these ACSs occurred within 1 month after aspirin withdrawal. This represents 4.1% of all coronary events but 13.3% of recurrences. Among those patients who relapsed, the incidence of ST-segment elevation ACS was higher in those who stopped aspirin when compared to the 332 patients who did not stop aspirin (39% vs. 18%; p = 0.001). Ten (20%) cases involved a thrombosis of an uncoated stent implanted on average 15.5 +/- 6.5 months previously. Mean delay between aspirin withdrawal and the acute coronary event was 10 +/- 1.9 days. Reasons for aspirin withdrawal included minor surgery in 7 cases, fibroscopy in 8 cases, dental treatment in 13 cases, bleeding in 3 cases, and patient non-compliance in 20 cases. Our results support the hypothesis that aspirin withdrawal in coronary patients may represent a real risk for the occurrence of a new coronary event. Many cases involved late uncoated-stent thrombosis. Assessment of the exact incidence of coronary recurrences after aspirin withdrawal will need prospective studies.Journal of the American College of Cardiology 03/2005; 45(3):456-9. · 14.09 Impact Factor
Current Cardiology Reviews, 2009, 5, 125-132
1573-403X/09 $55.00+.00 © 2009 Bentham Science Publishers Ltd.
Perioperative Management of Antiplatelet-Drugs in Cardiac Surgery
Raquel Ferrandis*, Juan V. Llau and Ana Mugarra
Department of Anaesthesiology and Critical Care Medicine, Hospital Clínic Universitari, València, Spain
Abstract: The management of coronary patients scheduled for a coronary artery bypass grafting (CABG), who are
receiving one or more antiplatelet drugs, is plenty of controversies. It has been shown that withdrawal of antiplatelet drugs
is associated with an increased risk of a thrombotic event, but surgery under an altered platelet function also means an
increased risk of bleeding in the perioperative period. Because of the conflict recommendations, this review article tries to
evaluate the outcome of different perioperative antiplatelet protocols in patients with coronary artery disease undergoing
and increasing. First treatment of occlusive coronary disease
involves percutaneous revascularization and many times one
or more stents placement. Any percutaneous coronary
intervention causes trauma to the vessel wall, rendering the
endoluminal surface thrombogenic and thus, dual anti-
platelet therapy (mostly aspirin and clopidogrel) is currently
recommended [1, 2].
The incidence of coronary artery disease (CAD) is high
bypass grafting (CABG), the traditional recommendation has
been to stop antiplatelet drugs between 7 to 10 days prior to
surgery . But, withdrawal of aspirin in patients with CAD
has been associated with a 2 to 4-fold increase in the risk of
death and myocardial infarction , being the major
independent predictor of stent occlusion [5, 6]. Thus, the
anaesthesiologist faces the dilemma of stopping the
antiplatelet treatment to avoid bleeding and risking
postoperative stent thrombosis, or to maintain the antiplatelet
therapy perioperatively to avoid the stent thrombosis, so
risking major blood loss and increased transfusion rate.
When these patients are scheduled for coronary artery
therapy in such a situation. Because of the conflict
recommendations, we undertook this systematic review of
the literature to evaluate the outcome of different
perioperative antiplatelet protocols in patients with CAD
We lack scientific evidence on the optimum perioperative
2. MAIN CHARACTERISTICS OF ANTIPLATELET
drugs (APD) are shown in Table 1 [7, 8].
The well established current indications of antiplatelet
particularly activation and subsequent aggregation, although
they make this effect through different ways showing
All of them are capable to inhibit platelet function,
*Address for correspondence to this author at the Raquel Ferrandis Comes,
Servicio de Anestesiología y Reanimación, Hospital Clínic Universitari,
Avda. Blasco Ibáñez, 17, 46010, Valencia, Spain; Tel: 00-34-96-3862653;
Fax: 00-34-96-3987831; E-mail: email@example.com
Recognized Indications of the Antiplatelet Drugs
Indications in Cardiology
• Acute myocardial infarction
• Acute coronary syndrome
- Stable angina
- Unstable angina/acute myocardial infarction without Q wave
• Percutaneous coronary angioplasty with coronary stent
• Atrial fibrillation*
• Patients undergoing CABG surgery
• Some patients with valvulopathies
Indications in Neurology
• Acute phase of stroke
• Secondary prevention of strokes in patients without emboligen
• Patient of valve prosthesis
• Emboligen carotid stenosis
• Carotid endarterectomy
• Patients with Antibodys Antifosfolípidos
• Peripheral artheriopaty with or without intermittent claudication
• Primary prevention in patients with cardiovascular risk
(*) In patients of less than 65 years without another associated risk factor.
different antiaggregant power (Table 2) [9, 10]. APD can be
classified into four groups:
1. Adenosin diphosphate (ADP) receptor antagonists,
such as the thienopyridine drugs ticlopidine and
clopidogrel, which reach their peak of activity after 3-5
days, producing a prolonged antiaggregant effect (7-10
days) due to its long half-life. The inhibitory effects of
126 Current Cardiology Reviews, 2009, Vol. 5, No. 2
Ferrandis et al.
Table 2. Antiaggregant Effect of Some of the Antiplatelet
Adenosin Diphosphate Receptor Antagonists
Ticlopidine 10-14 High
Clopidogrel 7-10 High
GPIIB/IIIA Receptor Antagonists
Eptifibatide 4 hours High
Tirofiban 4 hours High
Abciximab 48-72 hours High
Inhibitors Of Ciclooxygenase 1 Enzyme (COX-1)
ASA 7 High
Piroxicam 7 High
Indometacin 3 High
Ketorolac 2 High
Flurbiprofen 1 High
Ibuprofen 1 Moderate
Naproxen 2 Moderate
Ketoprofen 1 Moderate
Diclofenac 1 Moderate
Salsalate < 1 Weak
Diflunisal < 1 Weak
Paracetamol < 1 Weak
Proparacetamol < 1 Weak
Metamizol < 1 Weak
Rofecoxib 0 No
Celecoxib 0 No
Drugs That Increase The Intraplatelet Levels Of AMPC
Trifusal 7 High
Dipyridamole 1 Moderate
clopidogrel could be attained earlier by using 300 or 600
mg loading dose. Moreover, 600 mg double bolus has
been shown to achieve greater platelet inhibition than
conventional single loading doses .
2. GPIIb/IIIa receptor antagonists, of exclusively
intravenous use, which are more powerful, albeit with a
shorter-lasting action (24 h): eptifibatide, abciximab,
3. Drugs that increase the intraplatelet levels of AMPc.
The best known agent in this group is dipyridamole
(moderate antiaggregant effect lasting about 24 hours).
Other drugs are the I-2 prostaglandin (epoprostenol) and
its analog iloprost, both used by intravenous route with a
brief antiaggregant effect (< 3 h).
4. Inhibitors of ciclooxygenase 1 enzyme (COX-1). The
best known representatives are acetylsalicylic acid
(ASA) and non-esteroidal anti-inflammatory drugs
(NSAIDs). ASA is the most deeply studied one and its
antiaggregant effect takes place with the irreversible
blockade of COX-1, so its action lasts throughout all the
life of the platelet (7-10 days). Nevertheless, from the
third or fourth day usually there is enough number of
platelets to guarantee suitable haemostasis. The NSAIDs
also produce inhibition of platelet aggregation by a
similar mechanism to the ASA, although there are two
important differences: firstly the blocking effect of the
COX-1 is reversible, thus once the drug has been
eliminated from the circulation, the platelet function is
restored; secondly, there is a great difference between
the different NSAIDs in their capacity to inhibit COX-1
and, consequently, in its platelet antiaggregant action.
being continuously updated. In cardiologic patients, some
recent questions of development of the APD deserved to be
Actually the field of the indications of use of the APD is
The role of the aspirin in the primary prevention has
extended its prescription based on related factors of
cardiovascular and/or neurological risk. Moreover the
combination of two APD drugs (mainly ASA and
clopidogrel) in high risk patients is a practice more and
more extended .
Dual antiplatelet therapy has to be maintained at least 12
months after drug eluting stent placement and elective
surgery postponed; if surgery is necessary, at least ASA
should be maintained throughout the periperative period
and the patient operated under its antiaggregant effect
. Probably, in this patient a specific protocol of
antiaggregation in type, combination and duration of
APD need to be applied [13, 14].
The interindividual response to the APD is evident and
it does not seem that a valid universal pattern of
antiaggregation for all the patients exists.
antiplatelet therapy (Table 3) [15, 16]. From our point of
view, we could distinguish two groups: patients with chronic
treatment who are scheduled for cardiac surgery and patients
who require urgent surgery, most of them with double
Then, we face different type of patients who benefit from
3. CARDIOVASCULAR RISK AFTER ANTIPLATE-
LET DRUGS WITHDRAWAL
occlusive vascular events reduce the combined outcome of
any serious vascular event by about one quarter, non-fatal
myocardial infarction by one third, non-fatal stroke by one
quarter, and vascular mortality by one sixth (with no
apparent adverse effect on other death) . Aspirin has
been the most widely studied APD, with doses of 75-150 mg
daily at least as effective as higher daily doses. Keeping
patients on aspirin prior to surgery may help to attenuate the
inflammatory response during the operative period and may
also reduce cardiovascular events while awaiting surgery
The antiplatelet therapy in patients at high risk of
achieved with aspirin, although irreversible for target
platelets, lasts until a significant pool of new platelets is
produced. Nevertheless, a complete recovery of platelet
aggregation has been observed by day 3 (in 50% healthy
As we have previously described, the platelet inhibition
Perioperative Management of Antiplatelet-Drugs in Cardiac Surgery Current Cardiology Reviews, 2009, Vol. 5, No. 2 127
young men)  which seems due in part of a biological
platelet aggregation “rebound phenomenon”. In fact, after
aspirin discontinuation, the recovery of cyclooxigenase
activity may occur rapidly, with a heterogeneous synthesis of
thromboxane A2 by fresh platelets , which may have
possible hazardous effects in patients with cardiovascular
disease . Nevertheless, none of the guidelines support the
assessment of platelet reactivity by using point-of-care
cardiovascular risk of perioperative APD withdrawal, most
of them in non-cardiac surgery, but we did not find any study
comparing the cardiovascular risks of preprocedural APD
withdrawal directly against APD continuation. Instead of it,
we collect some studies that report the frequency of APD
(aspirin) withdrawal preceding
syndrome (Table 4) [4, 22-24].
Many studies have been recently published describing the
recommend cessation for 5-7 days before surgery. The
CURE study  and its sub-analyses show that cessation of
clopidogrel in these patients and for this time period is
associated with a 1% increase in the risk of myocardial
infarction. In non-surgical patients, with acute coronary
artery syndrome, the first 90-day interval after stopping
treatment with clopidogrel was associated with a
significantly higher risk of adverse events (incidence rate
ratio of 1.98) .
Talking about clopidogrel, most guidelines would
4. BLEEEDING RISK WITH PERIOPERATIVE
TREATMENT OF ANTIPLATELET DRUGS
procedural-bleeding risks with and without aspirin. Ex-
cluding studies on cardiac surgery, aspirin multiplied
baseline-bleeding rate by a factor of 1.5 , although
mortalities possibly caused by bleeding occurred only after
transurethral prostatectomy  and intracranial neuro-
There are many clinical studies comparing peri-
but there seems to have an increase of bleeding with a
tendency to need more transfusion requirements in patients
under the effect of aspirin [29-35]. Thus, in a recent
systematic review of randomized and observational studies
, pre-operative aspirin maintenance was associated with
a significant increase in the volume of post-operative
bleeding (mean difference 114 ml) and transfusion
requirements (mean difference 0.34 units), with not
significantly difference in the rates of reoperation; with the
subgroup analysis, the authors conclude that this bleeding
could be minimized by the use of aspirin doses less than 325
mg/day. Another metanalysis  shows similar results,
highlighting that the rate of platelet transfusion was similar
in both groups.
Focus on cardiac surgery, the results are heterogeneous
could be lower if the CABG surgery is performed off-pump,
and patients under the effect of aspirin seems to be at less
Bleeding complications and transfusion requirements
Recommendations on the Use of Antiplatelet Agents
Clinical Setting Recommendation Grade
Ischaemic heart disease
Chronic stable angina
Acute coronary syndrome without ST-segment elevation with PCI
Acute myocardial infarction with ST elevation
Acute myocardial infarction with ST elevation and with primary PCI
Aspirin or clopidogrel (as alternative)
Aspirin or clopidogrel + aspirin (more effective)
Aspirin or clopidogrel + aspirin (more effective)
i.v. GPIIb/IIIa inhibitors
i.v. GPIIb/IIIa inhibitors
Prior myocardial infarction Aspirin or clopidogrel (as alternative) 1A
Elective PCI + stent application
Clopidogrel or ticlopidine
PCI: Percutaneous coronary intervention. Grades of recommendation as defined by Guyatt et al. .
Table 4. Aspirin Withdrawal Preceding Acute Cardiovascular Syndrome
Number of Patients
Admitted for ACS
% Patients with Recent
Withdrawal of APD
% Withdrawal for Surgery
Time between Withdrawal
Aspirin and ACS
Collet, 2004 1358 73(5.4%) 74.38% 11.9±0.8
Collet, 2000 475 11(2.3%) 81% 10
Ferrari, 2005 1236 51(4.1%) 13.72% 10±1.9
ACS: acute cardiovascular syndrome
128 Current Cardiology Reviews, 2009, Vol. 5, No. 2
Ferrandis et al.
risk for bleeding or for reoperation due to postoperative
haemorrhage , even if aspirin is associated with
clopidogrel and not discontinued within 2 days of surgery
(no differences with the discontinuation more than 6 days
before surgery or between 2 and 5 days before surgery) .
Moreover, some articles have associated preoperative aspirin
maintenance with a decreased risk of mortality in CABG
patients without significant increase in haemorrhage, blood
product requirements, or related morbidities , even with
aspirin usage within the 5 days preceding surgery .
age, smaller body mass index, non-elective cases, 5 or more
distal anastomosis are more important risk factors for re-
exploration for bleeding after CABG than aspirin ingestion,
which is consistent with other previous studies [42, 43].
Thus, some surgical and patients characteristics as older
thienopyridines that antagonist irreversibly the platelet
adenosine diphosphate. It has showed to increase bleeding
after CABG in many articles [44-48], although there is
another report in which the maintenance of clopidogrel does
not increase bleeding or transfusion requirements . The
optimal waiting period after last clopidogrel administration
is not known but appears to be at least 5 days before CABG
; if the patient need to be antiaggregated near before
cardiac surgery, probably the best option is to use low-dose
aspirin perioperatively, once clopidogrel has been discon-
tinued . Finally, it has been published that a combined
preoperative treatment with heparin infusion could prevent
the increased blood loss associated to the administration of
clopidogrel, which may have been attributable to a conser-
vation of coagulation factors, as evidenced by the increased
plasma fibrinogen concentrations with combined prophy-
lactic treatment .
The other common drugs used as antiplatalet agent are
the intravenous GP IIb/IIIa platelet receptor antagonist
(tirofiban, eptifibate and abciximab). While eptifibatide and
tirofiban have a competitive binding and are rapidly cleared,
with an almost recovered platelet function in about 4 hours
, abciximab causes prolonged and irreversible effect,
with inhibition of platelet function and aggregation lasting
24-48 hours . Transfusion of platelets rapidly reverses
the inhibitory effects of abciximab , but it is of very little
utility during infusion or suddenly after eptifibatide or
tirofiban. No data are available in the literature on the impact
of tirofiban or eptifibatide treatment on emergency CABG;
however their short half-life and short-lasting action after
stopping the infusion is a potential advantage for the
performance of CABG with reduced risk of bleeding [55-
58], so no delay in surgery has been recommended . In
patients treated with abciximab, delaying emergency or
urgent CABG for 12 hours has been recommend [59, 60],
but other authors suggest rapid discontinuation of abciximab
infusion and undelayed intervention [61, 62]. In any case,
platelet transfusion should be considered only when
increased bleeding is encountered (not prophylactically), and
only after cessation of cardiopulmonary bypass .
Other drugs that have become increasingly common are
4.1. Methods to Avoid Bleeding
of methods intended to minimize perioperative transfusion:
In cardiac surgery, we should also take care of a variety
preoperative autologous donation, intra- and postoperative
cell salvage, and the use of drugs, such as aprotinin (a
protease inhibitor), desmopressin (that induces the release of
factor VIIIvW) and tranexamic acid (TXA) and epsilon-
aminocarproic acid (EACA) (that mainly inhibit plasmin
binding to fibrin).
number of allogenic transfusions after cardiac surgery and
the proportion of patients requiring reoperation because of
bleeding . Recent publications, however, have
questioned the safety of this agent, reporting not only an
increase in renal impairment but an increased risk of long-
term mortality following CABG surgery [65-67]. The FDA
and the EMEA have recently suspended its use, pending of a
complete analysis of a randomized prospective trial in
Canada (BART trial), which has shown similar results in
terms of mortality.
Many studies have shown that aprotinin decreased the
effect on reducing the proportion of patients receiving
transfusion after CABG , but its efficacy seemed to vary
depending on the use of aspirin. While some authors have
shown that desmopressin reduced the postoperative blood
loss and the transfusion requirements in patients treated with
aspirin within 7 to 5 days before surgery compared to
placebo [68-70], no effect was found in patients treated
within 2 days before CABG .
Desmopressin has not shown a statistically significant
allogenic blood, but has not statistically significant effect on
reoperations because of bleeding , both in on- and in off-
pump surgery . This effect is no consistent in all the
studies, excluding patients with APD, prophylactic use of
TXA did not result in any significant decrease in
postoperative bleeding in one study , but reduced
postoperative bleeding and fibrinolysis in another . In
patients treated with aspirin, the administration of a single
dose of TXA (30 mg/kg) immediately before cardio-
pulmonary bypass significantly reduced postoperative
bleeding and inhibited fibrinolysis .
The TXA decreases the portion of patients receiving
shown any statistically significant effect .
There are very few studies with EACA that have not
4.2. Monitors of Platelet Function Perioperatively
monitoring consists of a platelet count and prothrombin (PT)
and activated partial thromboplastin (aPTT) times, omitting
platelet function. However, these routine tests are insensitive
predictors of bleeding and perioperative changes in platelet
count shows poor correlation with changes in platelet
function . It would be helpful in the perioperative
management of APD to have a haemostatic test to identify
the patients at bleeding risk because of platelet dysfunction
related with the administration of any APD.
The current standard of care for perioperative coagulation
Optical platelet aggregometry is considered at present the
reference assay for diagnosis of platelet disorders ,
although it is not completely standardized, the laboratory
work up is complex and it is not possible to be performed
immediately before the surgery. The Platelet Function
Analyser (PFA-100) explores the platelet adhesive capacity,
Several tests could be used to assess the platelet function.
Perioperative Management of Antiplatelet-Drugs in Cardiac Surgery Current Cardiology Reviews, 2009, Vol. 5, No. 2 129
measuring the closure time taken for a platelet plug to
occlude an aperture in a membrane impregnated with
collagen and epinephrine or ADP ; ASA and clopidogrel
have been shown to prolong this closure time, but without
evident correlation with a perioperative bleeding. The
PlateletworksTM analyser measures the percentage of
aggregation of whole blood before and after the exposure to
ADP; its results are contradictory when compared with
optical aggregometry: good correlation for clopidogrel 
but of limited use for ASA . Thromboelastogrphy (TEG)
is a whole blood coagulation monitor, which can
demonstrate the alteration of platelet aggregation, but is
unable to detect the defects that occur with ASA or
demonstrate the ADP blockade caused by clopidogrel.
with perioperative bleeding and further clinical inves-
tigations are necessary in this field, although they can help
us to reduce the rate of reoperation for bleeding (TEG), in
part by helping to differentiate surgical from nonsurgical
bleeding , or to improve appropriate platelet transfusion
Unfortunately any of these tests has good correlation
5. GUIDELINES AND RECOMMENDATIONS
antiaggregant agents scheduled for cardiac surgery is a major
topic of interest and concern for all perioperative caregivers.
Many recommendations could be found in the available
published papers [8, 13, 14, 36, 37, 51, 82-85] and they
could be summarized as follows:
The management of patients under the effect of
1. Patient Treated with Aspirin
Aspirin should be maintained in patients at high risk for
arterial thrombotic complications. The optimal dose of
aspirin ranges between 75 and 325 mg and in the
perioperative period, in the majority of patients, it would
be enough the maintenance of low-dose of aspirin.
In the case of high risk of bleeding, some drugs that
decrease postoperative bleeding, as TXA or EACA
(with limited evidence to support the use of one agent
over the other) could be used; desmopresine might be
considered preoperatively only in patients with acquired
or inherited defects in primary haemostasis detected by
abnormal point-of-care test, as PFA-100.
2. Patient Treated with Clopidogrel
If the patient is on treatment with clopidogrel and needs
to be antiaggregated near before cardiac surgery,
probably the best option is to discontinue clopidogrel (at
least 5 days before surgery) and use low-dose aspirin
perioperatively (75-125 mg daily).
Dual antiplatelet therapy is associated with too high
bleeding risk. If it is mandatory to maintain this protocol
before surgery (probably only in patients with a drug-
eluting stent implanted less than 12 months ago), and
because of the concerns about premature discontinuation
of clopidogrel in these very high thrombotic risk
patients, several algorhythms have been proposed,
including the administration of an intravenous
glycoprotein IIb/IIIa inhibitor or unfractionated heparin
as “bridging therapy”. At present, there is no enough
evidence-based date to support this strategy.
3. Patient Treated with GP IIb/IIIa Inhibitor
In emergency surgery, if the patient is under the effect
of a glycoprotein IIb/IIIa inhibitor, it might be
considered the platelet transfusion (mainly if it is
abciximab) if there is too much bleeding; due to the
short-acting time of eptifibatide or tirofiban, the delay of
surgery is not recommended in the case of previous
administration of them.
4. Postoperative Treatment
If aspirin therapy has been interrupted before surgery, it
should be administered early after surgery, always
within 48 hours after CABG, and preferably within 6
hours after surgery. Dose ranges between 150-325
mg/day; optimal benefit could be reach with 325
mg/day, at least the first year.
There is no specific recommendation for resuming
clopidogrel after surgery, and it seems to have no
superiority over aspirin; if it is indicated instead of
aspirin, the timing for its administration could be the
same as for aspirin, but it is not recommended a loading
dose (300-600 mg) if first administration is close after
Blood salvage techniques use must be encouraged, as
the devices that conserve blood (intraoperative blood
salvage) or the use of autologous blood predonation or
Platelet transfusion is not indicated as prophylaxis to
avoid bleeding, even if the patient is under the effect of
aspirin or clopidogrel, and its administration must be
reserved if necessary to control excessive bleeding.
It is necessary an optimal preparation of the patient,
avoiding anaemia stimulating the administration of
drugs that increase preoperative blood volume, as
erythro-poietin in combination with iron.
Several guidelines recommend a multimodality app-
roach to blood conservation with the setting-up of
consensus algorhythms and point-of-care testing.
perioperative period of cardiac surgery requires close colla-
boration between cardiologists, surgeons and anaesthesio-
logists. It is necessary to avoid thrombotic complications
maintaining the antiaggregation, but balancing bleeding
The handicap of management of antiplatelet agents in the
increased bleeding if it is maintained until surgery, mainly if
Patients treated with long-term APD could be at risk for
130 Current Cardiology Reviews, 2009, Vol. 5, No. 2
Ferrandis et al.
there are any other outstanding variable as indicator of risk:
advanced age, preoperative anaemia, reoperative o complex
procedures, emergency operations or non-cardiac patient co-
morbidities. If the patient is under the effect of one or more
of these drugs the associated bleeding risk might be carefully
balanced and an alternative antiaggregation protocol could
be considered. Moreover, the drugs to minimize bleeding
could play an important role and might be in consideration.
faces up to the decision to maintain the treatment up to
surgery. The choice for one or the other option should be
based on the individual balance between the risk to develop
any cardiovascular event if the APD has been withdrawn and
the complications associated as result of the major bleeding
if the APD has been maintained until the day of the surgery.
The decision to stop the APD some days before surgery
above, we know that clopidogrel maintenance prior to
cardiac surgery is associated with a more blood product
usage, a 2-5 fold increase in the risk of re-exploration and
30-100% increase in the chest drain blood loss. The
withdrawal of clopidogrel prior to surgery, between 5 and 7
days, could be associated with a little increase of the risk of
myocardial infarction, estimated around 1% while the patient
is waiting for surgery . Between patients under aspirin,
its withdrawal 2-3 days before surgery could reduce
perioperative blood loss, risk for transfusion and reoperation
for bleeding. This practice seems safe for patients without
acute coronary syndromes, but for urgent cardiac surgery,
the risk of perioperative infarction is higher and the balance
is favourable to the maintenance of aspirin up to the day of
Summarising both possibilities and the comments stated
dation is to stop clopidogrel at least 5 days and, preferably,
10 days prior to surgery to minimize blood loss. In the case
of aspirin, the recommendation is to maintain it up to surgery
and beyond the time of surgery. But in the case of patients,
who are not at high risk for cardiac events, the routine
recommendation is to stop aspirin or clopidogrel prior to
surgery because of risk of bleeding and morbi-mortality
associated in these patients .
So, for patients scheduled for CABG, the recommen-
Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous
coronary interventions. The Task Force for Percutaneous Coronary
Interventions of the European Society of Cardiology. Eur Heart J
2005; 26: 804-47.
Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz
JL. Antithrombotic therapy
intervention: The Seventh ACCP Conference on Antithrombotic
and Thrombolytic Therapy. Chest 2004; 126: 576S-99S.
Bojar RM. In: Manual of Perioperative Care in Adult Cardiac
Surgery. Blackwell, Malden, Oxford, 2005
Collet JP, Montalescot G, Balnchet B, et al. Impact of prior use or
recent withdrawal of oral antiplatet agents on acute coronary
syndromes. Circulation 2004; 110: 2361-67.
Ia Kovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors and
aoutcomme of thrombosis after successful implantation of drug-
eluting stents. JAMA 2005; 293; 2126-30.
Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes
following aspirin withdrawal: an especial risk for late stent
thrombosis. J Am Coll Cardiol 2005; 45: 456-9.
Samama CM, Bastien O, Forestier F, et al. Antiplatelet agents in the
perioperative period: expert recommendations of the French Society
durin percuraneous coronary
of Anesthesiology and Intensive Care (SFAR) 2001 – Summary
statement. Can J Anesth 2002; 49: S26-S35.
Lecompte T, Hardy JF. Antiplatelet agents and perioperative
bleeding. Can J Anesth 2006; 53: S103-S12.
Patrono C, Coller B, Fitzgerald GA, Hirsh J, Roth G. Platelet active
drugs: the relationships among dose, effectiveness and side effects.
Chest 2004; 126: 234S-64S.
Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-
pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest
2001; 119: 64S-94S.
L’Allier PL, Ducrocq G, Pranno N, et al. Clopidogrel 600-mg
double loading dose achieves stronger platelet inhibition than
conventional regimens. Results from PREPAIR randomized study. J
Am Coll Cardiol 2008; 51: 1066-72.
Servin F. Low-dose aspirin and clopidogrel: how to act in patients
scheduled for day surgery. Curr Opin Anaesthesiol 2007; 20: 531-4.
Albaladejo P, Marret E, Piriou V. Samama CM. Perioperative
management of antiplatelet agents in patients with coornary stents:
recommendations of a French Task Force. Br J Anaesth 2006; 97:
Dalal AR, D’Souza S, Shulman RS. Brief review: Coronary drug-
eluting stents and anesthesia. Can J Anesth 2006; 53: 1230-43.
The Task Force on the use of antiplatelet agents in patients with
atherosclerotic cardiovascular disease of the European Society of
Cardiology. Espert consensus document on the use of antiplatelet
agents. Eur Heart J 2004; 25: 166-81.
Guyatt G, Schunëmann H, Cook D, et al. Grade of recommendation
for antithrombotic agents. Chest 2001; 119: 3S-7S.
Antithrombotic Trialists’ Collaboration. Collaborative meta-
analysis of randomized trials of antiplatelet therapy for prevention
ofdeath, myocardial infarction, and stroke in high risk patients. BMJ
2002; 324: 71-86.
Sun JCJ, Whitlock RW, Cheng J, et al. The effect of pre-operative
aspirin on bleeding, transfusion, myocardial infarction, and
mortality in coronary artery bypass surgery: a systematic review of
randomized and observatina studies. Eur Heart J 2008; 1057-71.
Jimenez AH, Stubbs ME, Tofler GH, Winther K, Williams GH,
Muller JE. Rapidity and duration of platelet suppression by enteric-
coated aspirin in healthy young men. Am J Cardiol 1992; 69: 258-
McDonald JW, Ali M. Recovery of cyclooxigenase activity after
aspirin in populations of platelets separated on stractan density
gradients. Prostaglandins Leukot Med 1983; 12: 245-52.
Beving H, Zhao C, Albage A, Ivert T. Abnormally high platelet
activity after discontinuation of acetylsalicylic acid treatment.
Blood Coagul Fybrinolysis 1996; 7: 80-4.
Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes
following aspirin withdrawal, a special risk for late stent
thrombosis. J Am Coll Cardiol 2005; 45: 456-9.
Collet JP, Himbert F, Steg PG. Myocardial infarction after aspirin
cessation in stable coronary artery disease patients. Int J Cardiol
2000; 76: 257-8.
Burguer W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose
aspirin for secondary cardiovascular prevention –cardiovascular
risks after its perioperative withdrawal versus bleeding risks with its
continuation- review a meta-analysis. J Intern Med 2005; 257: 399-
Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the
combination of clopidogrel and aspirin in patients undergoing
surgical revascularization for non ST-elevtion acute coronary
syndrome: th Clopidogrel in Unstable angina to prevent Recurrent
ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-8.
Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute
myocardial infarction associated with stopping clopidogrel after
acute coronary syndrome. JAMA 2008; 299: 532-9.
Thurston AV, Briant SL. Aspirin and post-prostatectomy
haemorrhage. Br J Urol 1993; 71: 574-6.
Palmer JD, Sparrow OC, Ianotti F. Postoperative hematoma: a 5-
year survey and identification of avoidable risk factors.
Neurosurgery 1994; 35: 1061-4.
Weightman WM, Gibbs NM, Weidmann CR, et al. The effect of
preoperative aspirin-free interval on red blood cell tansfusion
requirements in cardiac surgical patients. J Cardiothorac Vasc
Anesth 2002; 16: 54-8.
Mechanisms of action,
Perioperative Management of Antiplatelet-Drugs in Cardiac Surgery Current Cardiology Reviews, 2009, Vol. 5, No. 2 131
Lindblad B, Persson NH, Takolander R, Bergqvist D. does low dose
acetylsalicylic acid prevent stroke after carotid surgery? A double-
blind, placebo-controlled randomized trial. Stroke 1993; 24: 1125-8.
Kallis P, Tooza JA, Talbot S, Cowans D, Bevan DH, Treasure T.
Preoperative aspirin decreases platelet aggregation and increases
post-operative blood loss –a prospective, randomized, placebo
controlled, double-blind clinical trial in 100 patients with chronic
stable angina. Eur J Cardiothorac Thorac Surg 1994; 8: 404-9.
Morawski W, Sanak M, Cisowski M, et al. Prediction of the
excessive perioperative bleeding in patients undergoing coronary
artery bypass grafting: role of aspirin and platelet glycoprotein IIIa
polymorphism. J Thorac Cardiovasc Surg 2005; 130: 791-6.
Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K,
Henderson WG. Implications of preoperative administration of
aspirin in patients undergoing coronary artery bypass grafting.
Department of veterans Affairs Cooperative Study on Antiplatelet
Therapy. J Am Coll Cardiol 1990; 15: 15-20.
Rawitscher RE, Jones JW, McCoy TA, Lindsley DA. A prospective
study of aspirin’s effect on red blood cell loss in cardiac surgery. J
Cardiovasc Surg 1991; 32: 1-7.
Reich DL, Patel GC, Vela-Cantos F, Bodian C, Lansman S. Aspirin
does not increase homologous blood requirements in elective
coronary bypass surgery. Anesth Analg 1994; 79: 4-8.
Vuylsteke A, Oduro A, Cardan E, Latimer RD. Effects of aspirin in
coronary artery bypass grafting. J Cardiothorac Vasc Anaesth 1997;
Sun JCJ, Whitlock R, Cheng J, et al. The effect of pre-operative
aspirin on bleeding, transfusion, myocardial infarction, and
mortality in coronary artery bypass surgery: a systematic review of
randomized and observational studies. Eur Heart J 2008; 29: 1057-
Alghamdi AA, Moussa F, Fremes SE. Does the use of preoperative
aspirin increase the risk of bleeding in patients undergoing coronary
artery bypass grafting surgery? Systematic review and meta-
analysis. J Card Surg 2007; 22: 247-56.
Srinivasan AK, Grayson AD, Pullan DM, Fabri BM, Dihmi WC.
Effect of preoperative aspirin use in off-pump coronary artery
bypass operations. Ann Thorac Surg 2003; 76: 41-5.
Shim JK, Choi YS, Oh YJ, Bang SO, Yoo KJ, Kwak YL. Effects of
preoperative aspirin and clopidogrel therapy n perioperative blood
loss and blood transfusion requirements in patients undergoing off-
pump coronary artery bypass graft surgery. J Thorac Cardiovasc
Surg 2007; 134: 59-64.
Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative
aspirin use on mortality in coronary artery bypasses grafting
patients. Ann Thorac Surg 2000; 70: 1986-90.
Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy
is associated with improved postoperative outcomes in patients
undergoing coronary artery bypass grafting. Circulation 2005; 112:
Tuman KJ, McCarthy RJ, O’Connor CJ, McCarthy WE, Ivankovich
AD. Aspirin does not increase allogenic blood transfusion in
reoperative coronary artery surgery. Anesth Analg 1996; 83: 1178-
Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ.
Reexploration for bleeding after coronary artery bypass surgery:
risk factors, outcomes, and the effect of time delay. Ann Thorac
Surg 2004; 78: 527-34.
Yende S, Wunderink RG. Effect of clopidogrel on bleeding after
coronary artery bypass surgery. Crit Care Med 2001; 29: 2271-5.
Leong JY, Baker RA, Shah PJ, Cherian VK, Knight JL. Clopidogrel
and bleeding after coronary artery bypass graft surgery. Ann Thorac
Surg 2005; 80: 928-33.
Kapetantakis EI, Medlam DA, Petro KR, et al. Effect of clopidogrel
premedication I off-pump cardiac surgery: are we forfeiting the
benefits or reduced hemorrhagic squeal? Circulation 2006; 113:
Von Heyman C, Redlich U, Moritz M, et al. Aspirin and
clopidogrel taken until 2 days prior to coronary artery bypass graft
surgery is associated with increased postoperative drainage loss.
Thorac Cardiovasc Surg 2005; 53: 341-5.
Kang W, Theman TE, Reed JF, Stoltzfus J, Weger N. The effect of
preoperative clopidogrel on bleeding after coronary artery bypass
surgery. J Surg Educ 2007; 64: 88-92.
Karabulut H, Toraman F, Evrenkaya S, Goksel O, Tarcan S, Alhan
C. Clopidogrel does not increase bleeding and allogenic blood
transfusion in coronary artery surgery. Eur J Cardiothorac Surg
2004; 25: 419-23.
Reichert MG, Robinson AH, Travis JA, Hammon JW, Kon ND,
Kincaid EH. Effects of a waiting period after clopidogrel treatment
before performing coronary
Pharmacotherapy 2008; 28: 151-5.
Bavry AA, Lincoff AM. Is clopidogrel cardiovascular Medicine’s
double-edged sword? (Editorial). Circulation 2006; 113: 1638-40.
Pothula A, Sanchala VT, Nagappala B, Inchiosa MA. The effect on
preoperative antiplatelet/anticoagulant prophylaxis on postoperative
blood loss in cardiac surgery. Anesth Analg 2004; 98: 4-10.
Kleiman NS. Pharmacokinetics and pharmacodynamics of
glycoprotein IIb-IIIa inhibitors. Am Heart J 1999; 138: 263-75.
Tcheng JE. Differences among the parenteral platelet glycoprotein
IIb/IIIa inhibitors and implications for treatment. Am J Cardiol
1999; 83: 7E-11E.
Marso SP, Bhatt DL, Roe MT, et al. Enhanced efficacy of
eptifibatide administration in patients with acute coronary syndrome
requiring in-hospital coronary artery bypass grafting. Circulation
2000; 102: 2952-8.
Dyke CM, Bhatia D, Lorentz TJ, et al. Immediate coronary artery
bypass surgery after platelet inhibition with eptifibatatide: results
from PURSUIT. Platelet glycoprotein IIb/IIIa in unstable angina:
receptor suppression using integrelin therapy. Ann Thorac Surg
2000; 70: 866-71.
Bizarri F, Scolleta D, Tucci E, et al. Perioperative use of tirofiban
hydrocloride (Aggrastat) does not increase surgical bleeding after
emergency or urgent coronary artery bypass grafting. J Thorac
Cardiovasc Surg 2001; 122: 1181-5.
Shanmugan G. Tirofiban and emergency coronary surgery Eur J
Cardiothorac Surg 2005; 28: 546-50.
Cheng DK, Jackevivius CA, Seidelin P, Feindel C, Rouleau JL.
Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency
coronary artery bypass graft surgery. Can J Cardiol 2004; 20: 223-8.
Silvestry SC, Smith PK. Current status of cardiac surgery in the
abciximab-treated patient. Ann Thorac Surg 2000; 70: S12-9.
Le Narz LA. Coronary artery bypass in abciximab-treated patients.
Ann Thorac Surg 2000; 70: S38-42.
De Carlo M, Maselli D, Cortese B, et al. Emergency coronary
artery bypass grafting in patients with acute myocardial infarction
treated with glycoprotein IIb/IIIa receptor inhibitors. Int J Cardiol
2008; 123; 229-33.
Lincoff AM, LeNArz LA, Despotis GJ, et al. Abciximab and
bleeding during coronary surgery: results from the EPILOG and
EPISTENT trials. Improve long-term outcome with abciximab GP
IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibition in
STENTing. Ann Thorac Surg 2000; 70: 516-26.
Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on
clinical outcomes in coronary artery bypass graft surgery: a
systematic review and meta-analysis of randomized clinical trials. J
Thorac Cardiovasc Surg 2004; 128: 442-48.
Mangano DT, Tudor IC, Dietzel C. The risk assocaited with
aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65.
Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during
coronary-artery bypass grafting and risk of death. N Engl J Med
2008; 358: 771-83.
Shaw AD, Stafford-Smith M, White WD, et al. The effect of
aprotinin on outcome after coronary artery bypass grafting. N Engl
J Med 2008; 358: 784-93.
Have1 M, Grabenwoger F, Schneider J, et al. Aprotinin does not
decrease early graft patency after coronary artery bypass grafting
despite reducing postoperative bleeding and use of donated blood. J
Thorac Cardiovasc Surg 1994; 107: 807-10.
Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O.
Influence of aprotinin on early graft thrombosis in patients
undergoing myocardial revascularization. Eur J Cardiothorac Surg
1994; 8: 651-6.
Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for
coronary bypass operations: efficacy, safety, and influence on early
saphenous vein graft patency-a multicenter, randomized, double-
blind, placebo-controlled study. J Thorac Cardiovas Surg 1994;
Pleym H, Stenseth R, Wahba A, et al. Prophylactic treatment with
desmopressin does not reduce postoperative bleeding after coronary
surgery in patients treated with aspirin before surgery. Anesth
Analg 2004; 98: 578-84.
artery bypass grafting.
132 Current Cardiology Reviews, 2009, Vol. 5, No. 2
Ferrandis et al.
Casati V, Della Valle P, Benussi S, et al. Effects of tranexamic acid
on postoperative bleeding and related hematochemical variables in
coronary surgery: comparison between on-pump and off-pump
techniques. J Thorac Cardiovasc Surg 2004; 128: 83-91.
Andreasen JJ, Nielsen C. Prophylactic tranexamic acid in elective,
primary coronary artery bypass surgery using cardiopulmonary
bypass. Eur J Cardiothorac Surg 2004; 26: 311-7.
Santos ATL, Kalil RAK, Bauemann C, Pereira JB, Nesralla IA. A
randomized, double-blind, and placebo-controlled study with
tranexamic acid of bleeding and fibrinolytic activity after primary
coronary artery bypass grafting. Braz J Med Biol Res 2006; 39: 63-
Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O.
Single-dose tranexamic acid reduces postoperative bleeding after
coronary surgery in patients treated with aspirin until surgery.
Anesth Analg 2003; 96: 923-8.
Sié P, Steib A. Central laboratory and point of care assessment of
perioperative hemostasis. Can J Anesth 2006; 53: S12-20.
Howard-Alpe GM, de Bono J, Hudsmith L, Orr WP, Foex P, Sear
JW. Coronary artery stents and con-cardiac surgery. Br J Anaesth
2007; 98: 560-74.
Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC.
Comparison of modified thrombelastograph and plateletworks
whole blood assays to optical platelet aggregation for monitoring
reversal of clopidogrel inhibition in elective surgery patients. J Lab
Clin Med 2005; 145: 309-15.
Lennon MJ, Gibbs NM, Weigthman WM, McGuire D,
Michalopoulos N. A comparison of PlateletworksTM and platelet
aggregometry for the assessment of aspirin-related platelet
dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth
2004; 18: 136-40.
Essell JH, Martin TJ, Salinas
thromboelastography to bleeding time and standard coagulation
tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc
Anesth 1993; 7: 410-5.
Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse
CJ. Perioperative monitoring of primary and secondary haemostasis
in coronary artery bypass grafting. Semin Thromb Hemost 2005;
Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood
transfusion and blood conservation in cardiac surgery: The society
of thoracic surgeons and society of cardiovascular anesthesiologists
clinical practice guideline. Ann Thorac Surg 2007; 83: S27-86.
Chassot PG, Delabays A, Spanh DR. Perioperative antiplatelet
therapy: the case for continuing therapy in patients at risk of
myocardial infarction. Br J Anaesth 2007; 99: 316-28.
Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet
and anticoagulation management in cardiac surgery. Eur J
Cardiothorac Surg 2008; 34: 73-92.
Douketis JD, Berger PB, Dunn AS, et al. The perioperative
management of antithrombotic therapy. Chest 2008; 133: 299-339S.
J. Comparison of
Received: 09 May, 2008 Revised: 11 August, 2008 Accepted: 11 August, 2008